TY - JOUR
T1 - The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study
AU - Al Sulaiman, Khalid
AU - Aljuhani, Ohoud
AU - Korayem, Ghazwa B.
AU - Altebainawi, Ali F.
AU - Vishwakarma, Ramesh
AU - AlFaifi, Mashael
AU - Alsohimi, Samiah
AU - Alrayes, Aljoharah
AU - Albishi, Sara
AU - Alqahtani, Reem
AU - Alalawi, Mai
AU - Al Sulaihim, Ibrahim
AU - Alanazi, Thamer A.
AU - Alqahtani, Rahaf A.
AU - Almagthali, Alaa
AU - Jomah, Shahamah
AU - Alshlowi, Areej
AU - Alshammari, Tahani R.
AU - Alzahrani, Shahad S.
AU - Abdulqader, Marwa I.
N1 - The datasets used and/or analyzed during the current study are available from corresponding author on reasonable request.
We would like to thank the investigators who participated in this project from the Saudi critical care pharmacy research (SCAPE) platform.
PY - 2023/12/10
Y1 - 2023/12/10
N2 - The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = <.01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = <.01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs.
AB - The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = <.01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = <.01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs.
KW - COVID-19
KW - critically ill
KW - erythropoietin-stimulating agents
KW - ESA
KW - length of stay
KW - mortality
KW - ventilator-free days (VFDs)
UR - https://www.scopus.com/pages/publications/85179335626
U2 - 10.1177/10760296231218216
DO - 10.1177/10760296231218216
M3 - Article
C2 - 38073058
AN - SCOPUS:85179335626
SN - 1076-0296
VL - 29
SP - 1
EP - 10
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
ER -